EBR Systems Doubles Commercial Implants as Wireless Heart Device Adoption Surges
EBR Systems doubles commercial case volumes as WiSE adoption accelerates
EBR Systems has reported strong EBR Systems WiSE Q1 growth, with 41 commercial WiSE System implants completed during the quarter ended 31 March 2026. This represents more than double the case volumes recorded in Q4 2025, bringing total implants across the pilot phase and Limited Market Release to 71. The company expects to report preliminary revenue of US$2.25 million to US$2.36 million for Q1 2026, based on unaudited results subject to quarter-end closing adjustments.
The performance validates the company’s commercial execution strategy and reflects growing physician confidence in the wireless cardiac pacing technology. ASX: EBR shares are positioned to benefit from accelerating adoption as the Limited Market Release continues to scale.
When big ASX news breaks, our subscribers know first
What is the WiSE System and why does it matter?
The WiSE System is the world’s only wireless cardiac pacing device for heart failure patients. The technology enables cardiac pacing through a tiny endocardial implant roughly the size of a large grain of rice, eliminating the need for traditional pacing wires.
Traditional pacing leads have historically been the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. By removing the need for a coronary sinus lead to stimulate the left ventricle, the WiSE System addresses a longstanding clinical challenge in Cardiac Resynchronisation Therapy (CRT) for heart failure patients.
The technology represents a potentially superior pacing approach. Internal (endocardial) stimulation of the left ventricle is considered more anatomically correct than external pacing, a goal cardiac pacing companies have pursued for years. WiSE is currently available for sale only in the United States, with investigational status maintained in most other markets.
Limited Market Release gains momentum with 16 new purchase agreements
The Limited Market Release continued to advance during Q1 2026, with 16 additional purchase agreements signed with target centres. This brings the cumulative total to 37 purchase agreements (21 signed previously plus 16 new contracts).
Physician training also accelerated, with 22 physicians trained during the quarter. The total number of physicians now qualified to implant the WiSE System stands at 55. Hospital education on the process for New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) reimbursement schemes is progressing, whilst site activations and case scheduling continue to build the foundation for the remainder of 2026.
| Metric | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Physicians Trained (Quarter) | Data not disclosed | Data not disclosed | Data not disclosed | 22 |
| Physicians Trained (Cumulative) | Data not disclosed | Data not disclosed | 33 | 55 |
| Purchase Agreements Signed (Quarter) | Data not disclosed | Data not disclosed | Data not disclosed | 16 |
| Purchase Agreements Signed (Cumulative) | Data not disclosed | Data not disclosed | 21 | 37 |
| Cases Completed (Quarter) | Data not disclosed | Data not disclosed | Data not disclosed | 41 |
| Cases Completed (Cumulative) | Data not disclosed | Data not disclosed | Data not disclosed | 71 |
Purchase agreements represent committed institutional adoption, creating a pipeline of centres preparing to offer the WiSE System to eligible patients. The growing physician training base establishes scalable implant capacity across multiple sites, positioning the company to support increasing case volumes as hospital reimbursement processes are finalised.
CEO outlines disciplined execution strategy
Management emphasised systematic market development as the driver of Q1 performance.
John McCutcheon, President & Chief Executive Officer
“In Q1 2026, we made impressive progress across both our commercial and clinical programs. Case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness and the steady execution of our Limited Market Release. We also continued to advance important clinical initiatives, with further enrolment in both the WiSE-UP post-approval study and the TLC-AU feasibility study, helping to expand the body of evidence supporting the WiSE System across a broader patient population. We are encouraged by the momentum we are seeing and remain focused on disciplined execution, physician training, site activation and building the clinical and commercial foundation for broader adoption of the WiSE System.”
The commentary confirms three key focus areas driving the Limited Market Release:
- Physician training to expand the base of qualified implanters
- Site activation to establish reimbursement pathways at institutional level
- Building commercial foundation through purchase agreements and case scheduling
Clinical initiatives are advancing in parallel. Enrolment continues in both the WiSE-UP post-approval study and the TLC-AU feasibility study, building an evidence base that may support expanded indications or broader market access over time.
The next major ASX story will hit our subscribers first
Capital structure update and investor engagement
Following stockholder approval at the Special Meeting held on 12 March 2026, the Board resolved to implement a 1-for-10 reverse stock split of the company’s common stock. The reverse split became effective on 1 April 2026, with normal trading on a post-split basis expected to commence on 13 April 2026.
The company’s CHESS Depositary Interests (CDIs) were not consolidated. The conversion ratio changed from 1:1 to 10:1, meaning each CDI now converts into one-tenth of a share of common stock rather than one full share. Individual ownership ratios remain unchanged.
During Q1 2026, management maintained active engagement with the investment community, participating in several investor conferences:
- J.P. Morgan Healthcare Conference (San Francisco)
- Leerink Global Healthcare Conference (Miami)
- Bell Potter Healthcare Horizons Summit (Sorrento)
- Impact Investment Summit (Sydney)
- Evans & Partners Biotech Conference (Hong Kong)
Management also conducted an investor roadshow across Sydney and Melbourne in February. Active capital markets engagement signals management’s commitment to investor communication as the commercial rollout progresses.
What to watch for in 2026
The remainder of 2026 will focus on continued execution of the Limited Market Release. Site activations and case scheduling established during Q1 lay the foundation for sustained case volume growth as more centres become operational and physician experience deepens.
An investor webinar scheduled for 10 April 2026 at 09:00am AEST will provide further management commentary on the quarterly results and outlook. Clinical programmes, including the WiSE-UP post-approval study and TLC-AU feasibility study, represent evidence-building initiatives that could support broader market access or label expansion applications in future periods.
Near-term catalysts for investors include:
- Quarterly case volume updates demonstrating continued commercial momentum
- Additional purchase agreement signings as the Limited Market Release expands
- Enrolment milestones and potential data readouts from ongoing clinical studies
- Finalisation of hospital reimbursement processes under NTAP and TPT pathways
The preliminary revenue range of US$2.25 million to US$2.36 million for Q1 2026 reflects unaudited results subject to quarter-end closing adjustments. Final figures will be confirmed following completion of the financial close process and review by the company’s independent registered public accounting firm.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements hit the ASX.